897669-44-2

Basic information

• Product Name: 1,4-Piperidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester
• CAS NO: 897669-44-2
• Molecular Formula: C25H31NO4
• Molecular Weight: 409.525
• Mol File: 897669-44-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,4-Piperidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Piperidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester(897669-44-2)
• EPA Substance Registry System: 1,4-Piperidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester(897669-44-2)

Safety Data

• Hazardous Substances Data: 897669-44-2(Hazardous Substances Data)

Usage

Molecular Weight

399.5 g/mol

Functional Groups

Piperidine ring
Carboxylic acid groups
Ester groups
Phenylmethyl (benzyl) group
Tert-butyl group

Chemical Structure

A piperidine ring with two carboxylic acid groups, one at position 1 and the other at position 4. The 4-carboxylic acid group is esterified with a phenylmethyl group, and the 1-carboxylic acid group is esterified with a 1,1-dimethylethyl (tert-butyl) group.

Application

Used in the synthesis of pharmaceuticals and organic compounds.

Potential

Building block in the development of novel drugs
Precursor for the synthesis of various organic molecules

Importance

Versatile and valuable starting material for the creation of new pharmacological agents and chemical compounds
Of interest in the pharmaceutical industry for the development of new medications and therapeutic treatments

Biological Activity

Potential biological activity due to its structural diversity.

Field of Interest

Medicinal chemistry and drug development.

Upstream product

• 100-39-0 benzyl bromide 
• 167263-11-8 N-tert-butyloxycarbonyl-4-benzylpiperidine-4-carboxylic acid 

Relevant articles and documents

PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.